Multiple Myeloma Clinical Trials

There are 48 registered clinical trials for Multiple Myeloma in the TrialLens index.

Trials (48)

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma Phase 2 · Hoffmann-La Roche
Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma Phase 3 · Grupo de Estudos Multicentricos em Onco-Hematologia
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule Phase 1 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions N/A · University of Miami
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Phase 3 · University of Arkansas
Imaging in MGUS, SMM and MM Phase 2 · National Cancer Institute (NCI)
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Phase 1 · Bristol-Myers Squibb
Phase I Study of Sequential Cord Blood Transplants Phase 1 · Massachusetts General Hospital
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM Phase 1/2 · GlaxoSmithKline
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation N/A · Noha Mohamed Sharafeldin
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma Phase 1 · Eli Lilly and Company
Discontinuation Study N/A · University College Cork
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) Phase 1/2 · Xuzhou Medical University
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM Phase 1/2 · GlaxoSmithKline
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Phase 2/3 · National Research Center for Hematology, Russia
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma Phase 3 · Qilu Pharmaceutical Co., Ltd.
Thrombosis in Patients With Multiple Myeloma in an University Medical Center N/A · Catalina Codreanu
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma N/A · UNC Lineberger Comprehensive Cancer Center
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Phase 3 · Celgene
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma Phase 1 · Baylor College of Medicine
Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens Phase 1/2 · Hackensack Meridian Health
B-Cell Hematologic Malignancy Vaccination Registry N/A · Wake Forest University Health Sciences
Study of FasT CAR-T GC012F Injection NDMM Patients Early Phase 1 · Shanghai Changzheng Hospital
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation Phase 1 · University of Rochester
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) Phase 3 · Nanjing IASO Biotechnology Co., Ltd.
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project. N/A · Thomas Lund
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old Phase 3 · PETHEMA Foundation
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma Phase 2 · Stanford University
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) Phase 1 · Celgene
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Phase 1 · University of Chicago
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma Phase 1 · AbbVie
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma Phase 2 · Universitätsklinikum Hamburg-Eppendorf
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/2 · Washington University School of Medicine
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Phase 2 · National Cancer Institute (NCI)
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Phase 2 · University of California, San Francisco
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Phase 4 · Shandong Provincial Hospital
The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients N/A · Dr. Nicole Culos-Reed
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma Phase 2 · Valerio Therapeutics
RAT-HEMATO : Return to Work After Malignant Hemopathy N/A · University Hospital, Angers
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide Phase 1/2 · Fondazione EMN Italy Onlus
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment N/A · Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study. N/A · Centre Hospitalier Universitaire de la Guadeloupe
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 Phase 2 · University of Heidelberg Medical Center
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2 · Alfred Chung, MD
Short Course Daratumumab in Patients With Multiple Myeloma Phase 2 · Memorial Sloan Kettering Cancer Center
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy Phase 3 · Austrian Forum Against Cancer
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma Phase 3 · Nantes University Hospital

Related landscapes

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.